KLUS Pharma is currently seeking co-development partnerships to conduct clinical trials on COVID-19 patients in countries and regions most affected by the pandemic. Our investigational product (ACV200-17) is an inhaled peptide intended for prophylactic treatment of COVID-19 infection
ACE2 protein is widely expressed in the human respiratory tract. Coronavirus SARS-CoV-2 infects human cells by binding to ACE2 on the cell surface via interaction with viral S protein. Results from both nonclinical studies have demonstrated that ACV200-17 could be a promising drug to prevent the further spread of COVID-19.
ACV200-17 blocks interactions between ACE2 and the viral S protein in vitro.
Confirmed MOA and demonstrated efficacy in animal studies.
Safety studies showed good tolerance in mouse and monkey models when given as single intravenous administration and inhalation.
Demonstrated safety in healthy volunteers when given as single and repeated inhalation.
The product has an established GMP production capacity.
KLUS Pharma is actively seeking collaboration opportunities to accelerate the development and commercialization of ACV200-17 in the US and EU, in order to help combat the spread of the current COVID-19 pandemic.
KLUS Pharma Inc.
Cranbury, New Jersey, US